Bioventus Reports Q1 2026 Earnings with Revenue and EBITDA Growth
Bioventus reported Q1 2026 earnings with total revenue of $132 million, a 7% increase driven by growth across all business segments and a favorable rebate adjustment. Adjusted EBITDA rose 24% to $24 million, supported by higher revenue, improved gross margin, and favorable foreign exchange rates.
Topics: adjusted EBITDA cash flow debt reduction earnings revenue